ARTEMIS-008: Risvutatug rezetecan significantly improves overall survival in patients with relapsed SCLC

WCLC 2026

Lung, Respiratory and Thoracic Cancer

TAISHAN-302: Tambotatug pelitecan significantly improves overall survival in patients with relapsed SCLC

CHICAGO 2026

Multiple Myeloma (MM)

MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM

EHA 2026

Lymphoma

EPCORE DLBCL-1: Epcoritamab significantly improves PFS in patients with R/R LBCL

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Gastrointestinal Cancer

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort

J Clin Oncol

Moon AM, Yanagihara TK, Dawson LA, Yu JI, Lawrence TS, Kim TH, Yan M, Iwata H, Nabavizadeh N, Apisarnthanarax S, Dunne EM, Lock MI, Chuong MD, Chiang CL, Scorsetti M, Katoh N, Sioshansi S, Numata K, Liu HY, Iwamoto H, Wakatsuki M, Chen Y, Pollom EL, Gkika E, Jabbour SK, Munoz-Schuffenegger P, Dutta D, Hajj C, Ueno M, Hallemeier CL, Feldman AM, Méndèz Romero A, Tan X, Molla M, Tepper JE, Torres F, Reig M, EBRT Collaboration Group

doi: 10.1200/JCO-25-02399

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

Breast Cancer

Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

Int J Cancer

Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Quiering C, Roos C, Wöckel A

doi: 10.1002/ijc.70397

EHA 2026

Multiple Myeloma (MM)

MonumenTAL-3: Talquetamab-daratumumab regimens significantly improve PFS in patients with RRMM

EHA 2026

Multiple Myeloma (MM)

Related content

TAISHAN-302: Tambotatug pelitecan significantly improves overall survival in patients with relapsed SCLC

MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM

EPCORE DLBCL-1: Epcoritamab significantly improves PFS in patients with R/R LBCL

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort

IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

MonumenTAL-3: Talquetamab-daratumumab regimens significantly improve PFS in patients with RRMM

MajesTEC-9: Teclistamab significantly improves PFS and OS versus standard therapies in patients with RRMM